Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CMS (00867.HK) New Drug MG-K10 Marketing Application Accepted
Recommend 2 Positive 2 Negative 0 |
||||
|
||||
|
CMS (00867.HK) announced that the marketing authorization application in China for the Category 1 innovative drug anti-IL-4R?humanized monoclonal antibody injection MG-K10 (generic name: Kemeiqi Bai Monoclonal Antibody Injection), for the indication of seasonal allergic rhinitis, has been accepted by the National Medical Products Administration of China. The Group holds co-development rights and exclusive commercialization rights for the product. The drug is intended for adult patients with moderate-to-severe seasonal allergic rhinitis who have inadequate symptom control after treatment with intranasal corticosteroids. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
